Form 8-K - Current report:
SEC Accession No. 0001000694-25-000024
Filing Date
2025-05-08
Accepted
2025-05-08 08:26:56
Documents
16
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K nvax-20250508.htm   iXBRL 8-K 37113
2 EX-99.1 a1q25earningspressreleased.htm EX-99.1 112233
6 image.jpg GRAPHIC 8291
7 image_1.jpg GRAPHIC 122
  Complete submission text file 0001000694-25-000024.txt   299860

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvax-20250508.xsd EX-101.SCH 1795
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nvax-20250508_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvax-20250508_pre.xml EX-101.PRE 12520
18 EXTRACTED XBRL INSTANCE DOCUMENT nvax-20250508_htm.xml XML 2712
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 25924028
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)